GC Genome Corporation (KOSDAQ:340450)

Market Cap	194.65B
Revenue (ttm)	30.79B +12.8%
Net Income	2.44B
EPS	118.11
Shares Out	23.65M
PE Ratio	69.68
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	196,566
Average Volume	726,774
Open	8,310.00
Previous Close	8,250.00
Day's Range	8,100.00 - 8,460.00
52-Week Range	6,200.00 - 15,180.00
Beta	n/a
RSI	47.51
Earnings Date	Apr 3, 2026

About GC Genome

GC Genome Corporation operates as a clinical genome analysis company in South Korea. It offers hereditary cancer, tissue and liquid biopsy genetic, blood cancer, and homologous recombination deficiency tests under the Green Plan names; Guardant360, a blood genetic profiling test; Guardant Reveal, a liquid biopsy microscopic residual disease detection and recurrence monitoring test; and genetic rare disease testing services for chromosomal microarray, targeted exome sequencing, whole exome sequencing, and diagnostic genome sequencing. The compan...

• Industry: Medical - Equipment & Services
• Sector: Healthcare
• Founded: 2013
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 340450

Financial Performance

In 2024, GC Genome's revenue was 25.89 billion, a decrease of -5.15% compared to the previous year's 27.29 billion. Losses were -1.26 billion, 128.5% more than in 2023.